Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial-Reference-Cited by-同舟云学术

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

Published:2015-04-02 Issue:5 Volume:172 Page:1395-1406
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Bissonnette R.¹,Iversen L.²,Sofen H.³,Griffiths C.E.M.⁴,Foley P.⁵,Romiti R.⁶,Bachinsky M.⁷,Rottinghaus S.T.⁷,Tan H.⁷,Proulx J.⁷,Valdez H.⁸,Gupta P.⁷,Mallbris L.⁹,Wolk R.⁷

Affiliation:

1. Innovaderm Research; Montreal QC Canada

2. Aarhus University Hospital; Aarhus Denmark

3. Department of Medicine/Dermatology; UCLA School of Medicine; Los Angeles CA U.S.A

4. Salford Royal Hospital; Manchester Academic Health Science Centre; University of Manchester; Manchester U.K

5. Skin and Cancer Foundation Inc.; The University of Melbourne; Carlton Vic. Australia

6. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo; São Paulo Brazil

7. Pfizer Inc; Groton CT U.S.A

8. Pfizer Inc; New York NY U.S.A

9. Pfizer Inc; Collegeville PA U.S.A

Funder

Pfizer

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.13551/fullpdf

Reference21 articles.

1. Risk of myocardial infarction in patients with psoriasis;Gelfand;JAMA,2006

2. Psoriasis;Schon;N Engl J Med,2005

3. Psoriasis causes as much disability as other major medical diseases;Rapp;J Am Acad Dermatol,1999

4. Continuous versus intermittent therapy for moderate-to-severe psoriasis;Ramirez-Fort;Clin Exp Rheumatol,2013

5. Etanercept as monotherapy in patients with psoriasis;Leonardi;N Engl J Med,2003

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tofacitinib in dermatology: a potential opportunity for topical applicability through novel drug-delivery systems;Nanomedicine;2024-01

2. Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review;Life;2023-11-22

3. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease;Indian Journal of Dermatology, Venereology and Leprology;2023-09-05

4. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature;International Immunopharmacology;2023-09

5. Effects of Tofacitinib on Muscle Remodeling in Experimental Rheumatoid Sarcopenia;International Journal of Molecular Sciences;2023-08-24